monoclonal antibodies news from FierceBiotech

A joint venture between Crucell and DSM Biologics - Percivia -- has produced a new, more efficient approach to manufacturing monoclonal antibodies and proteins. By relying on human cell lines rather Read more...

Sanofi-Aventis has committed up to $500 million for the worldwide rights to Dyax's DX-2240 human monoclonal Read more...

In another display of monoclonal antibodies' appeal to drug developers, Maryland-based Humab Genome Sciences announced that it will team up with Xencor on drug development. Xencor uses its XmAb Read more...

In yet another sign of monoclonal antibodies' popularity among big drug developers, Wyeth has extend its evaluation of selected Raven Biotechnologies MAb antibodies. Raven, which signed a pact with Read more...

Looking for the hottest segment of the biotech industry? Then take a look at monoclonal antibodies (mAbs). A new Datamonitor report projects 14 percent annual growth in the market for the antibody Read more...

Ventana Medical Systems, which has been fighting a takeover offer from Roche, has inked a deal to acquire Spring BioScience--which makes rabbit monoclonal antibodies and other reagents--for $28.9 Read more...

Press Release: Archemix Corporation Announces Collaboration With Pfizer To Discover Aptamer Therapeutics

Read more...

GlaxoSmithKline has announced a deal to buy the UK's Domantis for $454 million--the latest in a string of major buyout deals. In this case, Glaxo is acquiring a leading developer of monoclonal antibodies and has attracted considerable attention to its programs for developing smaller antibodies that can be administered in a variety of ways and reach areas of the body that currently-used antibodies can't. Due to their relatively large molecular size, antibody therapies now have to be …

Read more...

Press Release: GlaxoSmithKline to Acquire Domantis for £230 Million

Read more...

France's Merieux Alliance has acquired a majority stake in India's Shantha Biotechnics. The deal gives Merieux a new development center for vaccines, therapeutic proteins and monoclonal antibodies. Shantha earned $20 million in revenue last year, making it India's fourteenth largest biotech company. Merieux sees the deal as a direct way to develop a beachhead in the Indian drug market.

"The stake will help us strengthen our presence within the country, which has strong potential in …

Read more...